Goldman Sachs’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Goldman Sachs’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-300,000	Closed	-$1.34M	–	6766
2013 Q2	$1.34M	Buy	+300,000	New	+$1.35M	﹤0.01%	4130

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Goldman Sachs's PGNX Position: Q2 2020 in Review

Goldman Sachs sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 338,888 shares — an estimated $1.29M sold.

Goldman Sachs first reported a position in PGNX in Q2 2013 and held it in 28 quarters. The position peaked at $7.88M in Q1 2017. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Goldman Sachs reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Goldman Sachs sold 338,888 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $1.29M.
Goldman Sachs first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 28 quarters.
Goldman Sachs's Progenics Pharmaceuticals Inc position peaked at $7.88M in Q1 2017.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Goldman Sachs's 13F filing for Q2 2020, filed 12 Aug 2020.